Article: Studies from Rene Descartes University, Medical Oncology Department describe new findings in prostate cancer therapy.

Data detailed in 'What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel' have been presented. In this recent article published in the journal Bju International, scientists in Paris, France conducted a study "To determine the benefit of starting early chemotherapy with docetaxel (the recommended first-line treatment) for patients with asymptomatic metastatic hormone-refractory prostate cancer (HRPC). Data were analysed from 145 patients with HRPC treated with chemotherapy between February 2000 and June 2002 in one French centre."

"Eligible patients were categorized into three groups ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!